AIM
LAB icon

Alambic Investment Management’s Standard BioTools LAB Stock Holding History

Alambic Investment Management’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-24,706
Closed -$86K – 235
2019
Q4 		$86K Sell
24,706
-10,070
-29% -$35.4K 0.07% 249
2019
Q3 		$161K Buy
+34,776
New +$274K 0.12% 231

Other funds holding LAB

Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ICM
Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return
EIP
Easterly Investment Partners Beverly, Massachusetts $1.31B AUM 18.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Alambic Investment Management's LAB Position: Q1 2020 in Review

Alambic Investment Management sold out of Standard BioTools (LAB) in Q1 2020, closing a stake of 24,706 shares — an estimated $86K sold.

Alambic Investment Management first reported a position in LAB in Q3 2019 and held it in 2 quarters. The position peaked at $161K in Q3 2019. 103 funds tracked by Wall St. Rank hold LAB as of Q1 2020.

  • Alambic Investment Management reported no remaining Standard BioTools position as of Q1 2020 after selling out during the quarter.
  • Alambic Investment Management sold 24,706 Standard BioTools shares in Q1 2020, an estimated $86K.
  • Alambic Investment Management first reported a position in Standard BioTools in Q3 2019 and held it in 2 quarters.
  • Alambic Investment Management's Standard BioTools position peaked at $161K in Q3 2019.
  • 103 funds tracked by Wall St. Rank held Standard BioTools as of Q1 2020.

Based on Alambic Investment Management's 13F filing for Q1 2020, filed 11 May 2020.